First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease
- Autores
- Ramirez, Juan C.; Parrado, Rudy; Sulleiro, Elena; de la Barra, Anabelle; Rodriguez, Marcelo; Villarroel, Sandro; Irazu, Lucía; Alonso-Vega, Cristina; Alves, Fabiana; Curto, María A; Garcia, Lineth; Ortiz, Lourdes; Torrico, Faustino; Gascon, Joaquim; Flevaud, Laurence; Molina, Israel; Ribeiro, Isabela; Schijman, Alejandro G.
- Año de publicación
- 2017
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Fil: Ramírez, Juan C. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina.
Fil: Parrado, Rudy. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia.
Fil: Sulleiro, Elena. Universitat Autònoma de Barcelona. Hospital Universitari Vall d'Hebron. Programa de Salut Internacional de l'Institut Català de la Salut; España.
Fil: de la Barra, Anabelle. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia.
Fil: Rodríguez, Marcelo. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
Fil: Villarroel, Sandro. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia.
Fil: Irazu, Lucía. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
Fil: Alonso-Vega, Cristina. Drugs for Neglected Diseases initiative; Suiza.
Fil: Alves, Fabiana. Drugs for Neglected Diseases initiative; Suiza.
Fil: Curto, María A. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina.
Fil: García, Lineth. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia.
Fil: Ortiz, Lourdes. Universidad Autónoma Juan Misael Saracho; Bolivia.
Fil: Torrico, Faustino. Fundación Ciencia y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente; Bolivia.
Fil: Gascón, Joaquim. ISGlobal. Barcelona Centre for International Health Research. Hospital Clínic-Universitat de Barcelona; España.
Fil: Flevaud, Laurence. Médecins Sans Frontières Operational Center Barcelona-Athens (OCBA); España.
Fil: Molina, Israel. Universitat Autònoma de Barcelona. Hospital Universitari Vall d'Hebron. Programa de Salut Internacional de l'Institut Català de la Salut; España.
Fil: Ribeiro, Isabela. Drugs for Neglected Diseases initiative; Suiza.
Fil: Schijman, Alejandro G. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina.
Real-Time PCR (qPCR) testing is recommended as both a diagnostic and outcome measurement of etiological treatment in clinical practice and clinical trials of Chagas disease (CD), but no external quality assurance (EQA) program provides performance assessment of the assays in use. We implemented an EQA system to evaluate the performance of molecular biology laboratories involved in qPCR based follow-up in clinical trials of CD. An EQA program was devised for three clinical trials of CD: the E1224 (NCT01489228), a pro-drug of ravuconazole; the Sampling Study (NCT01678599), that used benznidazole, both conducted in Bolivia; and the CHAGASAZOL (NCT01162967), that tested posaconazole, conducted in Spain. Four proficiency testing panels containing negative controls and seronegative blood samples spiked with 1, 10 and 100 parasite equivalents (par. eq.)/mL of four Trypanosoma cruzi stocks, were sent from the Core Lab in Argentina to the participating laboratories located in Bolivia and Spain. Panels were analyzed simultaneously, blinded to sample allocation, at 4-month intervals. In addition, 302 random blood samples from both trials carried out in Bolivia were sent to Core Lab for retesting analysis. The analysis of proficiency testing panels gave 100% of accordance (within laboratory agreement) and concordance (between laboratory agreement) for all T. cruzi stocks at 100 par. eq./mL; whereas their values ranged from 71 to 100% and from 62 to 100% at 1 and 10 par. eq./mL, respectively, depending on the T. cruzi stock. The results obtained after twelve months of preparation confirmed the stability of blood samples in guanidine-EDTA buffer. No significant differences were found between qPCR results from Bolivian laboratory and Core Lab for retested clinical samples. This EQA program for qPCR analysis of CD patient samples may significantly contribute to ensuring the quality of laboratory data generated in clinical trials and molecular diagnostics laboratories of CD. - Fuente
- PLoS One 2017; 12(11):e0188550
- Materia
-
Enfermedad de Chagas
Humanos
Monitoreo Fisiológico
Nitroimidazoles
Reacción en Cadena en Tiempo Real de la Polimerasa
Triazoles
Tripanocidas - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- Repositorio
- Institución
- Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
- OAI Identificador
- oai:sgc.anlis.gob.ar:123456789/1947
Ver los metadatos del registro completo
id |
SGCANLIS_e60dda56e5ed3bb507fc66ff2413f791 |
---|---|
oai_identifier_str |
oai:sgc.anlis.gob.ar:123456789/1947 |
network_acronym_str |
SGCANLIS |
repository_id_str |
a |
network_name_str |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN |
spelling |
First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas diseaseRamirez, Juan C.Parrado, RudySulleiro, Elenade la Barra, AnabelleRodriguez, MarceloVillarroel, SandroIrazu, LucíaAlonso-Vega, CristinaAlves, FabianaCurto, María AGarcia, LinethOrtiz, LourdesTorrico, FaustinoGascon, JoaquimFlevaud, LaurenceMolina, IsraelRibeiro, IsabelaSchijman, Alejandro G.Enfermedad de ChagasHumanosMonitoreo FisiológicoNitroimidazolesReacción en Cadena en Tiempo Real de la PolimerasaTriazolesTripanocidasFil: Ramírez, Juan C. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina.Fil: Parrado, Rudy. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia.Fil: Sulleiro, Elena. Universitat Autònoma de Barcelona. Hospital Universitari Vall d'Hebron. Programa de Salut Internacional de l'Institut Català de la Salut; España.Fil: de la Barra, Anabelle. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia.Fil: Rodríguez, Marcelo. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Villarroel, Sandro. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia.Fil: Irazu, Lucía. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Alonso-Vega, Cristina. Drugs for Neglected Diseases initiative; Suiza.Fil: Alves, Fabiana. Drugs for Neglected Diseases initiative; Suiza.Fil: Curto, María A. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina.Fil: García, Lineth. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia.Fil: Ortiz, Lourdes. Universidad Autónoma Juan Misael Saracho; Bolivia.Fil: Torrico, Faustino. Fundación Ciencia y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente; Bolivia.Fil: Gascón, Joaquim. ISGlobal. Barcelona Centre for International Health Research. Hospital Clínic-Universitat de Barcelona; España.Fil: Flevaud, Laurence. Médecins Sans Frontières Operational Center Barcelona-Athens (OCBA); España.Fil: Molina, Israel. Universitat Autònoma de Barcelona. Hospital Universitari Vall d'Hebron. Programa de Salut Internacional de l'Institut Català de la Salut; España.Fil: Ribeiro, Isabela. Drugs for Neglected Diseases initiative; Suiza.Fil: Schijman, Alejandro G. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina.Real-Time PCR (qPCR) testing is recommended as both a diagnostic and outcome measurement of etiological treatment in clinical practice and clinical trials of Chagas disease (CD), but no external quality assurance (EQA) program provides performance assessment of the assays in use. We implemented an EQA system to evaluate the performance of molecular biology laboratories involved in qPCR based follow-up in clinical trials of CD. An EQA program was devised for three clinical trials of CD: the E1224 (NCT01489228), a pro-drug of ravuconazole; the Sampling Study (NCT01678599), that used benznidazole, both conducted in Bolivia; and the CHAGASAZOL (NCT01162967), that tested posaconazole, conducted in Spain. Four proficiency testing panels containing negative controls and seronegative blood samples spiked with 1, 10 and 100 parasite equivalents (par. eq.)/mL of four Trypanosoma cruzi stocks, were sent from the Core Lab in Argentina to the participating laboratories located in Bolivia and Spain. Panels were analyzed simultaneously, blinded to sample allocation, at 4-month intervals. In addition, 302 random blood samples from both trials carried out in Bolivia were sent to Core Lab for retesting analysis. The analysis of proficiency testing panels gave 100% of accordance (within laboratory agreement) and concordance (between laboratory agreement) for all T. cruzi stocks at 100 par. eq./mL; whereas their values ranged from 71 to 100% and from 62 to 100% at 1 and 10 par. eq./mL, respectively, depending on the T. cruzi stock. The results obtained after twelve months of preparation confirmed the stability of blood samples in guanidine-EDTA buffer. No significant differences were found between qPCR results from Bolivian laboratory and Core Lab for retested clinical samples. This EQA program for qPCR analysis of CD patient samples may significantly contribute to ensuring the quality of laboratory data generated in clinical trials and molecular diagnostics laboratories of CD.Public Library of Science2017-12-27info:ar-repo/semantics/articuloinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://sgc.anlis.gob.ar/handle/123456789/194710.1371/journal.pone.0188550PLoS One 2017; 12(11):e0188550reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁNinstname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"instacron:ANLIS#PLACEHOLDER_PARENT_METADATA_VALUE#datasetsPloS oneenginfo:eu-repo/semantics/openAccess2025-09-29T14:30:33Zoai:sgc.anlis.gob.ar:123456789/1947Institucionalhttp://sgc.anlis.gob.ar/Organismo científico-tecnológicoNo correspondehttp://sgc.anlis.gob.ar/oai/biblioteca@anlis.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:a2025-09-29 14:30:33.521Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"false |
dc.title.none.fl_str_mv |
First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease |
title |
First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease |
spellingShingle |
First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease Ramirez, Juan C. Enfermedad de Chagas Humanos Monitoreo Fisiológico Nitroimidazoles Reacción en Cadena en Tiempo Real de la Polimerasa Triazoles Tripanocidas |
title_short |
First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease |
title_full |
First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease |
title_fullStr |
First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease |
title_full_unstemmed |
First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease |
title_sort |
First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease |
dc.creator.none.fl_str_mv |
Ramirez, Juan C. Parrado, Rudy Sulleiro, Elena de la Barra, Anabelle Rodriguez, Marcelo Villarroel, Sandro Irazu, Lucía Alonso-Vega, Cristina Alves, Fabiana Curto, María A Garcia, Lineth Ortiz, Lourdes Torrico, Faustino Gascon, Joaquim Flevaud, Laurence Molina, Israel Ribeiro, Isabela Schijman, Alejandro G. |
author |
Ramirez, Juan C. |
author_facet |
Ramirez, Juan C. Parrado, Rudy Sulleiro, Elena de la Barra, Anabelle Rodriguez, Marcelo Villarroel, Sandro Irazu, Lucía Alonso-Vega, Cristina Alves, Fabiana Curto, María A Garcia, Lineth Ortiz, Lourdes Torrico, Faustino Gascon, Joaquim Flevaud, Laurence Molina, Israel Ribeiro, Isabela Schijman, Alejandro G. |
author_role |
author |
author2 |
Parrado, Rudy Sulleiro, Elena de la Barra, Anabelle Rodriguez, Marcelo Villarroel, Sandro Irazu, Lucía Alonso-Vega, Cristina Alves, Fabiana Curto, María A Garcia, Lineth Ortiz, Lourdes Torrico, Faustino Gascon, Joaquim Flevaud, Laurence Molina, Israel Ribeiro, Isabela Schijman, Alejandro G. |
author2_role |
author author author author author author author author author author author author author author author author author |
dc.subject.none.fl_str_mv |
Enfermedad de Chagas Humanos Monitoreo Fisiológico Nitroimidazoles Reacción en Cadena en Tiempo Real de la Polimerasa Triazoles Tripanocidas |
topic |
Enfermedad de Chagas Humanos Monitoreo Fisiológico Nitroimidazoles Reacción en Cadena en Tiempo Real de la Polimerasa Triazoles Tripanocidas |
dc.description.none.fl_txt_mv |
Fil: Ramírez, Juan C. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina. Fil: Parrado, Rudy. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia. Fil: Sulleiro, Elena. Universitat Autònoma de Barcelona. Hospital Universitari Vall d'Hebron. Programa de Salut Internacional de l'Institut Català de la Salut; España. Fil: de la Barra, Anabelle. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia. Fil: Rodríguez, Marcelo. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina. Fil: Villarroel, Sandro. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia. Fil: Irazu, Lucía. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina. Fil: Alonso-Vega, Cristina. Drugs for Neglected Diseases initiative; Suiza. Fil: Alves, Fabiana. Drugs for Neglected Diseases initiative; Suiza. Fil: Curto, María A. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina. Fil: García, Lineth. Universidad Mayor de San Simón. Instituto de Investigaciones Biomédicas; Bolivia. Fil: Ortiz, Lourdes. Universidad Autónoma Juan Misael Saracho; Bolivia. Fil: Torrico, Faustino. Fundación Ciencia y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente; Bolivia. Fil: Gascón, Joaquim. ISGlobal. Barcelona Centre for International Health Research. Hospital Clínic-Universitat de Barcelona; España. Fil: Flevaud, Laurence. Médecins Sans Frontières Operational Center Barcelona-Athens (OCBA); España. Fil: Molina, Israel. Universitat Autònoma de Barcelona. Hospital Universitari Vall d'Hebron. Programa de Salut Internacional de l'Institut Català de la Salut; España. Fil: Ribeiro, Isabela. Drugs for Neglected Diseases initiative; Suiza. Fil: Schijman, Alejandro G. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina. Real-Time PCR (qPCR) testing is recommended as both a diagnostic and outcome measurement of etiological treatment in clinical practice and clinical trials of Chagas disease (CD), but no external quality assurance (EQA) program provides performance assessment of the assays in use. We implemented an EQA system to evaluate the performance of molecular biology laboratories involved in qPCR based follow-up in clinical trials of CD. An EQA program was devised for three clinical trials of CD: the E1224 (NCT01489228), a pro-drug of ravuconazole; the Sampling Study (NCT01678599), that used benznidazole, both conducted in Bolivia; and the CHAGASAZOL (NCT01162967), that tested posaconazole, conducted in Spain. Four proficiency testing panels containing negative controls and seronegative blood samples spiked with 1, 10 and 100 parasite equivalents (par. eq.)/mL of four Trypanosoma cruzi stocks, were sent from the Core Lab in Argentina to the participating laboratories located in Bolivia and Spain. Panels were analyzed simultaneously, blinded to sample allocation, at 4-month intervals. In addition, 302 random blood samples from both trials carried out in Bolivia were sent to Core Lab for retesting analysis. The analysis of proficiency testing panels gave 100% of accordance (within laboratory agreement) and concordance (between laboratory agreement) for all T. cruzi stocks at 100 par. eq./mL; whereas their values ranged from 71 to 100% and from 62 to 100% at 1 and 10 par. eq./mL, respectively, depending on the T. cruzi stock. The results obtained after twelve months of preparation confirmed the stability of blood samples in guanidine-EDTA buffer. No significant differences were found between qPCR results from Bolivian laboratory and Core Lab for retested clinical samples. This EQA program for qPCR analysis of CD patient samples may significantly contribute to ensuring the quality of laboratory data generated in clinical trials and molecular diagnostics laboratories of CD. |
description |
Fil: Ramírez, Juan C. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr. Héctor N. Torres; Argentina. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017-12-27 |
dc.type.none.fl_str_mv |
info:ar-repo/semantics/articulo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://sgc.anlis.gob.ar/handle/123456789/1947 10.1371/journal.pone.0188550 |
url |
http://sgc.anlis.gob.ar/handle/123456789/1947 |
identifier_str_mv |
10.1371/journal.pone.0188550 |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
#PLACEHOLDER_PARENT_METADATA_VALUE# datasets PloS one |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Public Library of Science |
publisher.none.fl_str_mv |
Public Library of Science |
dc.source.none.fl_str_mv |
PLoS One 2017; 12(11):e0188550 reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁN instname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán" instacron:ANLIS |
reponame_str |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN |
collection |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN |
instname_str |
Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán" |
instacron_str |
ANLIS |
institution |
ANLIS |
repository.name.fl_str_mv |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán" |
repository.mail.fl_str_mv |
biblioteca@anlis.gov.ar |
_version_ |
1844621857995620352 |
score |
12.559606 |